In a new paper published online by Nature Genetics, researchers from Dana-Farber Cancer Institute (DFCI) and the Broad Institute systematically investigated somatic copy number alterations of noncoding regions across cancers, integrating genomic, epigenomic, and transcriptomic data.
The team found six super-enhancer regions that are focally amplified across different cancer types, including two that are associated with overexpression of the MYC oncogene, suggesting that this type of modification may be a common mechanism activating cancer driver genes.
The team, which was led by senior author Matthew Meyerson and first authors Xiaoyang Zhang, Peter Choi, and Joshua Francis – all of Broad and DFCI – also used genome-editing technologies to validate the oncogenic function of these focally amplified super-enhancers.
Study suggests common mechanism activating cancer driver genes (2015, December 23)
retrieved 17 July 2019
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.
Your feedback will go directly to Science X editors.
E-mail the story
Study suggests common mechanism activating cancer driver genes